Lawsuits claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs

DEC 15 (Reuters) – A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly alleging patients lost some or all of their eyesight while taking the companies’ blockbuster weight loss drugs before a judge in Pennsylvania.

The U.S. Judicial Panel on Multidistrict Litigation, which manages complex federal litigation, agreed with the plaintiffs that the cases should be centralized in their own multi-district litigation (MDL) in Philadelphia federal court rather than added to the existing mass litigation in the same court over gastrointestinal side effects of the drugs.